Switching from intravenous to subcutaneous administration of rituximab for non-Hodgkin diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) resulted in similar efficacy with no new safety issues.
MYC-rearrangement within 2 years after diagnosis may affect the prognosis of patients with diffuse large B-cell lymphoma.
A new study looks into whether disease stage at diagnosis affects the occurrence and location of a second primary malignancy in DLBCL.
Delays in CAR T-cell therapy may significantly decrease gains in survival and productivity for patients with diffuse large B-cell lymphoma and pediatric acute lymphoblastic leukemia.
Researchers looked at the pre-transplant PET/CT Deauville scores of patients with relapsed or refractory diffuse large B-cell lymphoma treated with R-DHAC to see if patients with a higher score had a higher risk for treatment failure.
Researchers from the Mayo Clinic in Rochester, Minn. examined the disease histology and outcomes of patients with diffuse large B-cell lymphoma and a concurrent lymphoma.
A combination of ibrutinib, lenalidomide, and rituximab was tested on patients with relapsed or refractory diffuse large B-cell lymphoma, particularly those with non-GCB subtype.
Cell of origin and dual expressor/double-hit status may not confer prognosis as originally suspected.
Researchers looked at the effect of diagnostic wait time on survival outcomes for patients with diffuse large B-cell lymphoma.
A Mayo Clinic study tested metformin, believed to have anti-lymphoma activity, among patients with newly diagnosed diffuse large B-cell lymphoma or follicular lymphoma.